Masters moments: Ian Woosnam wins in 1991 and gets a lift from caddie ‘Wobbly’ | Golf News

first_imgWe continue our look back through the Augusta archives by remembering Ian Woosnam’s dramatic victory at The Masters in 1991. As the countdown continues towards the delayed 2020 Masters, we take you back to 1991 at Augusta National and Ian Woosnam’s maiden major triumph.Woosnam arrived for his fourth Masters appearance ranked second in the world behind defending champion Nick Faldo, and with five top-10 finishes to his name in major championships.The Welshman was five off the pace after an opening-round 72, but he responded with an impressive 62 on day two which got him within two strokes of the halfway leader, and home favourite, Tom Watson. 2:25 Woosnam receives the green jacket from Nick Faldo Woosnam receives the green jacket from Nick Faldo

Ressence Type 5X waterproof watch replicates the design of a car’s dashboard » Gadget Flow

first_imgThe Ressence Type 5X waterproof watch features a unique design with markings on the bezel that are related to a car’s dashboard. In particular, the bezel is divided into two distinct parts. The first replicates the warmup of an engine and the second dedicates itself to the Turbos cooling. The dial and sub-dials draw inspiration from cars, with the Lancia Delta Futurista car being the motivation behind the graphics. Furthermore, this waterproof watch is legible from low angles thanks to the oil. It continues working in water up to 100m and the rubber accessory makes it practical and comfortable for wearing while driving. Finally, the olive green shade on the dial softens and darkens due to the presence of oil in the dial. This creates a unique effect and improves visibility, too. – Advertisement –last_img read more

With H1N1 resistance, CDC changes advice on flu drugs

first_imgDec 19, 2008 (CIDRAP News) – Increased resistance to oseltamivir (Tamiflu), the leading influenza drug, has prompted federal health officials to change their advice about flu treatment, saying clinicians for now should consider using zanamivir (Relenza) or a combination of two drugs for patients suspected of having influenza A.The Centers for Disease Control and Prevention (CDC) today said 49 of 50 influenza A/H1N1 viruses tested so far this season have shown resistance to oseltamivir. But all the isolates remained sensitive to zanamivir and to the two older flu drugs, amantadine and rimantadine.H1N1 is one of the three viral types and subtypes included in season flu vaccine; the others are A/H3N2 and B.”When influenza A (H1N1) virus infection or exposure is suspected, zanamivir or a combination of oseltamivir and rimantadine are more appropriate options than oseltamivir,” the CDC said in today’s advisory. “Local influenza surveillance data and laboratory testing can help with physician decision-making regarding the choice of antiviral agents for their patients.”But Dr. Anthony Fiore, a medical epidemiologist in the CDC’s Influenza Division, said rapid flu tests don’t identify the viral subtype, and many areas don’t have good flu surveillance data. “This problem really does complicate deciding what kind of antiviral to use,” he told CIDRAP News.At the same time, he said US flu activity remains low so far this season, and the resistant H1N1 viruses seem no more virulent than susceptible ones. In its weekly surveillance update today, the CDC said 3 states have reported local flu activity, while 36 states have reported only sporadic cases. Another 11 states have reported no flu cases yet.The CDC said vaccination should continue as the primary method for preventing the flu, as the oseltamivir-resistant H1N1 viruses are antigenically similar to the H1N1 strain in this year’s vaccine.Resistance emerged last seasonSince January 2006, oseltamivir and zanamivir have been the only antivirals recommended for flu in the United States. At that point the CDC advised clinicians to stop using amantadine and rimantadine, known as the adamantanes, because H3N2 viruses had become highly resistant to them. Today’s interim guidance puts the adamantanes back in the recommendations.Significant H1N1 resistance to oseltamivir emerged in the United States and a number of other northern hemisphere countries during the 2007-08 flu season. Overall, 10.9% of tested H1N1 viruses in this country showed resistance, according to the CDC.But resistance rose to nearly 100% in some southern hemisphere countries, particularly Australia and South Africa, in their 2008 season, said Fiore.The CDC’s new interim recommendations for healthcare providers include the following:Review local or state flu virus surveillance data weekly to determine which types and subtypes are circulating.Consider using rapid tests that can distinguish types A and B. Fiore said some rapid tests can do this, but others can’t.Patients who test positive for type B can be given either oseltamivir or zanamivir if treatment is indicated.If a patient tests positive for type A, zanamivir should be considered if treatment is indicated. Oseltamivir should be used alone only if local surveillance data suggest that circulating viruses are likely to be A/H3N2 or B. A combination of oseltamivir and rimantadine is an acceptable alternative, and may be necessary for patients who can’t take zanamivir, which is taken by inhalation and is not licensed for children younger than 7 years. Amantadine can replace rimantadine if the latter is not available.If a patient tests negative on a rapid flu test, clinicians should still consider treatment, depending on local flu activity and clinical signs and symptoms. (Fiore said rapid tests are not very sensitive and work better in children than adults.) If treatment is indicated, zanamivir or a combination of oseltamivir and rimantadine should be considered.Where available, testing for viral subtypes can guide treatment. For patients with an H3N2 or B virus, either oseltamivir or zanamivir can be used; for an H1N1 infection, zanamivir or the combination of oseltamivir and rimantadine can be used.What pushed the CDC to make the new recommendations, said Fiore, was the high level of resistance in the H1N1 viruses tested, plus the fact that most of the viruses tested so far this season have been H1N1.The latter factor could easily change, he said. “Last season at this time, H1N1 was the most common [subtype], but a month later they were a distant third place. That could happen again. So these are interim guidelines, and one hope we have is that clinicians will recognize that things are a little complicated this year and keep track of the recommendations that come out.”Fiore said polymerase chain reaction (PCR) tests that can identify flu subtypes are now available, but their use is mostly limited to specialty labs, such as state health departments. Once samples arrive at the lab, the tests take a couple of hours. “So if you were going to wait to decide therapy, you’re going to end up with a pretty substantial delay,” he said.Also, he said many areas don’t have good local flu surveillance data. “That advice to look at local data is probably not going to be useful in a lot of areas,” he commented.On the other hand, he noted, “We don’t have much flu activity of any kind right now. . . . And things could continue to evolve and change.”He added, “The fact is that most people don’t get antiviral treatment in the first place. And the resistant viruses are not any more dangerous or virulent, so the person is not going to know if they have resistant flu.”Experts air practical concernsKristine Moore, MD, MPH, medical director of the University of Minnesota Center for Infectious Disease Research and Policy, which publishes CIDRAP News, said she’s not surprised by the sudden spike in antiviral resistance in this year’s circulating H1N1 strain. She said influenza A viruses have a strong tendency to mutate rapidly, and that increasing use of oseltamivir has placed more selective pressure on the virus.The quick emergence of antiviral resistance and the CDC’s revised treatment recommendation have important implications for pandemic flu planning, Moore said. A rapid change affecting treatment could happen in a pandemic influenza strain. “This teaches us not to rely on any one strategy,” she said.William Schaffner, MD, chairman the Department of Preventive Medicine at the Vanderbilt University School of Medicine, told CIDRAP News that healthcare providers expect a little disconcerting news each flu season. “But we got the prize in the Cracker Jack box early this year,” he said.If physicians need to prescribe treatment for some of their patients who have influenza, they’re going to have to get a sense of what strains are circulating in their area, which will be a change for many practitioners.Schaffner advises physicians to use the rapid test to guide treatment. Patients who have the B strain will still benefit from oseltamivir treatment.Though the CDC recommends zanamivir as an option for treating patients who have A strains, Schaffner said many physicians aren’t as familiar with teaching patients how to use the inhaler. “Pharmacists are going to be very helpful,” he said.Some experts questioned if physicians will have enough information about what influenza subtypes are circulating in their area. Kristen Ehresmann, RN, MPH, manager of immunization, tuberculosis, and international health at the Minnesota Department of Health (MDH) in St. Paul, told CIDRAP News that many state public health laboratories have the reagents used to distinguish influenza subtypes.However, she said getting a timely picture of the circulating strains will be a challenge. Though most public health labs easily handle sentinel surveillance samples, they have a more limited ability to process randomly submitted samples.”Every state’s resources are different,” Ehresmann said, adding that the MDH uses a weekly e-mail listserv to update clinicians on the status of circulating influenza strains.Schaffner said he contacted Vanderbilt’s virus lab today and asked if they could start subtyping the influenza A strains and communicating the results to Tennessee’s health department and the general medical community.”This is new for the labs, but there is an urgency for this information,” he said. “Doctors will have to learn how to keep up with information about the circulating strains.”The experts who spoke with CIDRAP News said they were concerned about the nation’s supply of zanamivir, given the CDC’s revised antiviral recommendations. Moore said even if the supply seems adequate, some regions of the country may still experience shortages.However, GlaxoSmithKline, the maker of zanamivir, said today in a press release that it has sufficient supplies to meet the needs of the 2008-09 influenza season and that pharmacies can get the medicine from their wholesalers.Moore and Schaffner both expressed concerns about the combination (oseltamivir and rimantadine) therapy alternative recommended for patients who can’t take zanamivir. “It’s a reasonable recommendation, but its efficacy and safety have never been demonstrated in humans,” Moore said.Added impetus to vaccinateA silver lining in the CDC’s antiviral resistance warnings and treatment recommendations is that they strengthen the rationale for seasonal flu vaccination, the experts said. “These events speak to the value of vaccination and not counting on being able to treat influenza after the fact,” Ehresmann said.Schaffner, who is also president-elect of the National Foundation for Infectious Diseases, said vaccine supplies are abundant this year, and an examination of early viral isolates suggests that the vaccine is a good match with the circulating strains.This year so far looks like a typical flu season, and activity usually peaks in February, he said, “so there’s still time to be protected by getting the vaccine through December and into January.”See also:CDC interim antiviral guidance for 2008-2009CDC weekly flu surveillance updatelast_img read more

Trafigura Steps into Petrochemicals Market with Altis

first_imgCommodity trading company Trafigura Group has entered into a joint venture agreement with trading and logistics company Altis Group International in an effort to create a commodity petrochemical trading business, with a focus on bulk liquid chemicals.The joint venture has been formed between Trafigura and senior executives from the petrochemical trading industry, including the current management team of Altis.It will include two new trading entities – the already existing Altis Group International for the US, based in Houston and Altis International (Singapore), which will have a branch office in Geneva.Trafigura senior managers Chris Clarkson, Head of Gasoline Trading and Tom Jay, who until recently headed the Deals Desk for refined metals, bulk and concentrates, will join the boards of the new venture.“We believe that the time is right to start exploring the potential of this market,” Tom Jay said.“The market for petrochemicals is expected to grow significantly over the next few years, with Altis well placed to capture a share of this market,” he added.The new venture will be led by a team of industry veterans with more than 100 years of combined relevant experience, according to Trafigura.“The new global venture with Trafigura will be transformative not only for Altis and its employees but for all of our commercial partners. Teaming up with Trafigura will accelerate our growth and ability to expand our trading reach globally,” Jeff McNear, President of the Altis Group International management team, explained.Formed in 2014, Altis focuses on the trade of bulk liquid chemicals. Active in the petrochemical markets on a worldwide basis, with expertise in handling shipping and logistics for a wide range of chemicals, the employees and commercial activities of Altis will transition into the US-based and international companies and serve as the trading platform for the new venture.Founded in 1993, Trafigura is one of the largest physical commodities trading groups in the world. Trafigura sources, stores, transports and delivers a range of raw materials — including oil and refined products and metals and minerals.last_img read more

Guus Hiddink urges Chelsea to relieve goalscoring burden from Diego Costa

first_imgChelsea interim manager Guus Hiddink has told his attacking players that the goalscoring burden does not fall on Diego Costa alone. Press Association “Normally you see teams like Leicester or Palace or Watford starting surprisingly well, let’s say until the leaves are going to fall, and then they will have some problems. But they’ve managed to maintain their good performances. “First of all, they have a good balance in their team. They’re not just doing it on willpower, but on quality. “If you rely just on willpower, then you will fall some day. But they have the quality as well. Watford have very good strikers. Leicester too. “The rest are very well organised. I think this will last until the end of the season.” “Diego is focusing very much on his job and that’s a lot of responsibility. He’s brave and he likes to be like that,” Hiddink said. “It’s a lot of responsibility, but not just on Diego. He has a big temper and wants to perform and is keen to score, but the other attacking players must play a part in assists and goals. It’s not just him. “There’s a lot of technical skill in the midfield and attacking positions. We have to see how the players can become even more productive and take the next step. “We’re trying to get them into good positions in the box so that their high quality has more effect. “They have the quality. Now they have to be productive with assists or goals. It’s not just about Diego.” The ailing Premier League champions face Crystal Palace at Selhurst Park on Sunday hoping to avoid the double after losing 2-1 to their London rivals in August. In a remarkable season Chelsea find themselves three points above the relegation zone while Palace occupy fifth place, an example of a wider trend in which smaller clubs are upsetting the established order. “I don’t know if it’s true the bigger clubs will eventually pull through,” Hiddink said. Costa is the Blues’ highest scorer in the Barclays Premier League this season with five goals, two of which were delivered in the recent 2-2 draw with Watford – Hiddink’s first match in charge since replacing Jose Mourinho. Hiddink knows he must get the best out of his main forward as Radamel Falcao and Loic Remy are in the treatment room, but he believes the Spain marksman needs help from his team-mates. last_img read more